Clinical and laboratory characteristics of adolescents with platelet function disorders and heavy menstrual bleeding

Table 1 Clinical and laboratory characteristics at presentation for postmenarcheal adolescents with documented platelet function disorders

Clinical & Laboratory Characteristics	Heavy Menstrual Bleeding (n=43)			Non-Heavy Menstrual Bleeding (n=20)			P
Age (y) at PFD diagnosis (mean; range)	14.5 ± 3.5; 3 - 20			10.9 ± 3.5; 5 - 17			<.01
Prior to menarche	6 (14)			14 (70)
At menarche	10 (23)			0
After menarche	27 (63)			6 (30)
Age (y) at menarche (mean; range)	11.8 ± 1.0; 9 - 15			12.1 ± 1.5; 9 - 16			.36
Interval (y): PFD-dx-to menarche (mean)	2.54 ± 3.09			1.48 ± 3.11			<.01
	after menarche			prior to menarche
Age (y) at HMB onset (mean; range)	13.5 ± 1.9; 9 - 18			0
At menarche	10 (23)			0
After menarche	33 (77)			0
Interval (y): from menarche-to-HMB onset (mean; range)	1.79 ± 1.4; 0–5.0			0
PBAC score ≥ 100	43 (100)			0
Ethnicity
Caucasian	35 (81)			16 (80)			1.0
African-American	4 ( 9)			1 (5)
Asian	1 ( 2)			0
Hispanic	1 ( 2)			1 (5)
Multiethnic	2 ( 5)			2 (10)
Family History of Bleeding Tendencies
Positive	36 (83.7)			17 (85)			.41
Negative	7 (16.3)			3 (15)
	ABO	Rh(D)		ABO	Rh(D)
Blood Group Types		+	−		+	−
Group O	33 (76.0)	27	6	14 (70.0)	13	1	.037^†
Group A	9 (21.0)	9	0	6 (30.0)	6	0
Group B	1 ( 3.0)	1	0	0	0	0
Hematocrit (%) (mean)*	37.3 ± 4.8			38.0 ± 3.9			.7
MCV (fL) (mean)^*	85.4 ± 5.1			86.0 ± 5.9			.75
Platelet count (μ/L) (mean)	284.0 ± 62.3			285.0 ± 71.0			.99
PT (s) (mean)	12.2 ± 0.81			12.5 ± 0.94			.35
aPTT (s) (mean)	31.8 ± 6.3			31.4 ± 4.0			.82
			ABO-Adjusted	VWF Levels
von Willebrand Factor Assays^‡	O		A,B	O		A,B
VWF:RCo (%) (mean)	69.7±18.7		91.9±16.2	84.5±21.2		101.2±29.6	.13
VWF:Ag (%) (mean)	88.0±10.3		100.7±13.6	88.3±10.1		104.0±24.6
FVIII:C (%) (mean)	119.0 ± 66.7			104.0 ± 27.9
VWF:RCo/VWF:Ag ratio (mean)	0.912 ± 0.235			0.960 ± 0.274

aPTT=activated partial thromboplastin time; dx=diagnosis; FVIII:C=Factor VIII activity; MCV=mean corpuscular volume; PT= prothrombin time;VWF=von Willebrand factor; VWF:RCo=ristocetin cofactor activity; VWF:AG=VWF antigen; PBAC=pictorial bleeding assessment chart; U.S.=United States.
Data for both groups are presented as means ± standard deviations or n (%).
^*Reference intervals (females) at corresponding ages ≤13yrs or >14yrs:Hematocrit, 35-45% or 37-47%; MCV, 78-95fL or 78-100fL; platelet count, 140,000-450,000μ/L.
^† P-value applies only to ABO blood group distribution differences between HMB-group & a comparable U.S. population.^21,22 ^‡von Willebrand Factor Assay reference intervals adjusted for blood groups O & A,B: A,B:VWF:RCo=37.5-117.1 & 48 206.1;VWF:Ag=48.1-146 & 50.7-193.7, respectively.

ISSN: 2162-3619